In addition, we analyzed that gene alteration style in patients with targeted therapy and found SETD2, NPM1, CSF1R, BRCA1, FAT1, CCND1, PTPN11, and ARID1A gene mutations are key genes to determine prognosis in RCC patients .Thiesen et al. reported that up to 30% ccRCC patients had CSF1R gene mutations.41 This evidence concerns the gene FAT1 and renal cell carcinoma.